Equities Analysts Set Expectations for argenex Q3 Earnings

Key Points

• Wedbush recently raised its Q3 2025 earnings estimate for argenex to $6.72 per share, significantly up from the previous estimate of $4.22, while maintaining an "Outperform" rating and a $715 target price.
• In addition to Wedbush, multiple analysts have upgraded their ratings for argenex, with a consensus average rating of "Buy" and a target price of $736.81.
• Argenex reported a strong quarterly performance with $3.74 earnings per share, surpassing analysts' expectations of $2.84, along with a revenue of $866.79 million compared to anticipated $776.82 million.

argenex SE (NASDAQ:ARGX - Free Report) - Wedbush boosted their Q3 2025 earnings estimates for shares of argenex in a report released on Thursday, July 31st. Wedbush analyst D. Nierengarten now expects that the company will earn $6.72 per share for the quarter, up from their prior estimate of $4.22. Wedbush currently has a "Outperform" rating and a $715.00 target price on the stock. The consensus estimate for argenex's current full-year earnings is $3.13 per share. Wedbush also issued estimates for argenex's Q4 2025 earnings at $7.42 EPS, FY2026 earnings at $32.90 EPS, FY2027 earnings at $44.31 EPS and FY2028 earnings at $61.09 EPS.

A number of other equities research analysts have also commented on ARGX. Robert W. Baird upgraded shares of argenex from a "neutral" rating to an "outperform" rating and set a $680.00 price target for the company in a report on Tuesday, May 13th. JMP Securities set a $699.00 price target on shares of argenex in a report on Wednesday, May 14th. Wells Fargo & Company upped their price target on shares of argenex from $741.00 to $756.00 and gave the company an "overweight" rating in a report on Thursday. Baird R W upgraded shares of argenex from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of argenex from a "hold" rating to a "buy" rating in a report on Tuesday, July 8th. Nineteen analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, argenex currently has an average rating of "Buy" and an average target price of $736.81.

argenex Stock Performance

Shares of argenex stock opened at $673.80 on Monday. argenex has a 52-week low of $475.65 and a 52-week high of $689.13. The stock has a market capitalization of $41.24 billion, a price-to-earnings ratio of 34.55, a price-to-earnings-growth ratio of 0.93 and a beta of 0.39. The company has a fifty day moving average of $571.11 and a 200-day moving average of $596.29.

argenex (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $3.74 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.84 by $0.90. argenex had a net margin of 40.98% and a return on equity of 21.06%. The company had revenue of $866.79 million during the quarter, compared to analysts' expectations of $776.82 million.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. GeoWealth Management LLC increased its stake in shares of argenex by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after acquiring an additional 18 shares in the last quarter. Greenleaf Trust increased its stake in shares of argenex by 3.5% in the 1st quarter. Greenleaf Trust now owns 624 shares of the company's stock worth $369,000 after acquiring an additional 21 shares in the last quarter. Rakuten Securities Inc. increased its stake in shares of argenex by 56.4% in the 1st quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock worth $36,000 after acquiring an additional 22 shares in the last quarter. Sequoia Financial Advisors LLC grew its position in argenex by 1.3% during the 1st quarter. Sequoia Financial Advisors LLC now owns 1,829 shares of the company's stock valued at $1,083,000 after purchasing an additional 24 shares during the last quarter. Finally, M&T Bank Corp grew its position in argenex by 0.6% during the 1st quarter. M&T Bank Corp now owns 4,296 shares of the company's stock valued at $2,542,000 after purchasing an additional 27 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.